Appendix Table D-7Progression free survival outcomes for KQ 1 and 2

Author, YearInterventionProgression DefinitionLiver PFS Median (months) (95% CI)Overall PFS Median (months) (95% CI)
Albert - 2011TACEStudy Treatment53
Martin - 2011TACE with DEBStudy Treatment1511
Vautravers-Dewas - 2011SBRTNRNRNR
Nace - 2011RENRNRNR
Aliberti - 2011TACE w/DEBStudy TreatmentNR23
Cosimelli - 2010REStudy TreatmentNR3.7 (2.6 to 4.9)
Stintzing - 2010SBRTNRNRNR
Nishiofuku - 2010HAIStudy Treatment4.6 (2.8 to 6.3)2.8 (2 to 3.6)
Kim - 2009SBRTStudy TreatmentNR10
Cianni - 2009REStudy TreatmentNR9.3
Mulcahy - 2009RENRNRNR
Martin – 2012REStudy Treatment5.1 (2.4 to 5.9)NR
Hong - 2009TACENRNRNR
Sato - 2008RENRNRNR
Vogl - 2008HAINRNRNR
Jakobs - 2008RENRNRNR
Rowe - 2007SIRTNRNRNR
Jiao - 2007SIRTNRNRNR
Fiorentini - 2007TACE with DEBNRNRNR
Jakobs - 2006RFANRNRNR
Lewandowski - 2005RENRNRNR
Lim - 2005SIRTStudy TreatmentNR5.3

CI: confidence interval; DEB: drug eluting bead; KQ: Key Question; HAI: hepatic arterial infusion; NR: not reported; pFS: Progression free survival; RE: radioembolization; RFA: radiofrequency abalation; SBRT: stereotactic body radiation therapy; SIRT: selective internal radiation therapy; TACE: transarterial chemoembolization

From: Appendix D, Evidence Tables

Cover of Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer
Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer [Internet].
Comparative Effectiveness Reviews, No. 93.
Belinson S, Chopra R, Yang Y, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.